These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29474204)

  • 21. Does Race Play a Role in Complications and Outcomes of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms?
    Peseski AM; Saliba AN; Althouse SK; Sayar H
    Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):30-38. PubMed ID: 33607101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombosis in myeloproliferative neoplasms.
    Falanga A; Marchetti M
    Semin Thromb Hemost; 2014 Apr; 40(3):348-58. PubMed ID: 24610470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical characteristics and management of children, adolescents, and young adults with Philadelphia chromosome-negative myeloproliferative neoplasms].
    Sugimoto Y
    Rinsho Ketsueki; 2023; 64(10):1314-1325. PubMed ID: 37914247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients.
    Wille K; Huenerbein K; Jagenberg E; Sadjadian P; Becker T; Kolatzki V; Meixner R; Marchi H; Fuchs C; Griesshammer M
    Eur J Haematol; 2022 Feb; 108(2):154-162. PubMed ID: 34719056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study.
    De Stefano V; Ghirardi A; Masciulli A; Carobbio A; Palandri F; Vianelli N; Rossi E; Betti S; Di Veroli A; Iurlo A; Cattaneo D; Finazzi G; Bonifacio M; Scaffidi L; Patriarca A; Rumi E; Casetti IC; Stephenson C; Guglielmelli P; Elli EM; Palova M; Rapezzi D; Erez D; Gomez M; Wille K; Perez-Encinas M; Lunghi F; Angona A; Fox ML; Beggiato E; Benevolo G; Carli G; Cacciola R; McMullin MF; Tieghi A; Recasens V; Isfort S; Marchetti M; Griesshammer M; Alvarez-Larran A; Vannucchi AM; Rambaldi A; Barbui T
    Blood; 2020 Jan; 135(5):381-386. PubMed ID: 31869407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet count and mean platelet volume predict outcome in adults with Eisenmenger syndrome.
    Martin-Garcia AC; Arachchillage DR; Kempny A; Alonso-Gonzalez R; Martin-Garcia A; Uebing A; Swan L; Wort SJ; Price LC; McCabe C; Sanchez PL; Dimopoulos K; Gatzoulis MA
    Heart; 2018 Jan; 104(1):45-50. PubMed ID: 28663364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
    Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
    Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study (CATS).
    Riedl J; Kaider A; Reitter EM; Marosi C; Jäger U; Schwarzinger I; Zielinski C; Pabinger I; Ay C
    Thromb Haemost; 2014 Apr; 111(4):670-8. PubMed ID: 24306221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms.
    Gugliotta L; Iurlo A; Gugliotta G; Tieghi A; Specchia G; Gaidano G; Scalzulli PR; Rumi E; Dragani A; Martinelli V; Santoro C; Randi ML; Tagariello G; Candoni A; Cattaneo D; Ricco A; Palmieri R; Liberati MA; Langella M; Rago A; Bergamaschi M; Monari P; Miglio R; Santoro U; Cacciola R; Rupoli S; Mastrullo L; Musto P; Mazzucconi MG; Vignetti M; Cortelezzi A; Vianelli N; Martino B; De Stefano V; Passamonti F; Vannucchi AM;
    Leuk Res; 2016 Jul; 46():18-25. PubMed ID: 27107744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging Role of Neutrophils in the Thrombosis of Chronic Myeloproliferative Neoplasms.
    Ferrer-Marín F; Cuenca-Zamora EJ; Guijarro-Carrillo PJ; Teruel-Montoya R
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular risk in a contemporary cohort of patients with myeloproliferative neoplasms'.
    Mehta D; Alimam S; McLornan DP; Henry JA; Ahmed S; Ghosh AK; Tyebally S; Walker JM; Patel R; Amerikanou R; O'Nions J; Wilson AJ; Lambert J; Sekhar M; Chen D
    Curr Res Transl Med; 2024 Mar; 72(1):103420. PubMed ID: 38262189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management and Outcome of Venous Thrombosis in Patients with Myeloproliferative Neoplasms: Data from the Israeli MPN Working Group.
    Gutwein O; Lavi N; Barzilai M; Shacham-Abulafia A; Leader A; Chubar E; Dally N; Shapira S; Mishchenko E; Ellis M; Koren-Michowitz M
    Acta Haematol; 2021; 144(4):438-445. PubMed ID: 33316809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.).
    Kreher S; Ochsenreither S; Trappe RU; Pabinger I; Bergmann F; Petrides PE; Koschmieder S; Matzdorff A; Tiede A; Griesshammer M; Riess H; ; ;
    Ann Hematol; 2014 Dec; 93(12):1953-63. PubMed ID: 25307456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient outcomes in myeloproliferative neoplasm-related thrombosis: Insights from the National Inpatient Sample.
    Ulanja MB; Beutler BD; Antwi-Amoabeng D; Apanga PA; Moody AE; Willyard CE; Gullapalli N; Boampong-Konam K; Bowman AT
    Thromb Res; 2020 Oct; 194():72-81. PubMed ID: 32788124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
    Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
    Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mean platelet volume does not seem to relate to thrombosis or posterior uveitis in Behçet's disease.
    Ricart JM; España F; Navarro S; Todolí J; Miguel De la Fuente J; Vayá A
    Clin Hemorheol Microcirc; 2013 Jan; 54(1):51-7. PubMed ID: 22750994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcome prediction from mean platelet volume in patients undergoing percutaneous coronary intervention in Korean cohort: Implications of more simple and useful test than platelet function testing.
    Choi SW; Choi DH; Kim HW; Ku YH; Ha SI; Park G
    Platelets; 2014; 25(5):322-7. PubMed ID: 23909871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship Between Mean Platelet Volume and Pulmonary Embolism in Patients With Deep Vein Thrombosis.
    Icli A; Aksoy F; Turker Y; Uysal BA; Alpay MF; Dogan A; Nar G; Varol E
    Heart Lung Circ; 2015 Nov; 24(11):1081-6. PubMed ID: 26146200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brachial-ankle pulse wave velocity and mean platelet volume as predictive values after percutaneous coronary intervention for long-term clinical outcomes in Korea: A comparable and additive study.
    Seo HJ; Ki YJ; Han MA; Choi DH; Ryu SW
    Platelets; 2015; 26(7):665-71. PubMed ID: 25383727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Thrombosis and platelet dysfunction in myeloproliferative neoplasms].
    Mornet C; Galinat H; Mingant F; Ianotto JC; Lippert E
    Rev Med Interne; 2020 May; 41(5):319-324. PubMed ID: 32008800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.